Secondary Cytoreduction Improves Progression-Free Survival in Platinum-Sensitive, Relapsed Ovarian Cancer
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.
Ovarian Cancer
Lack of Standardized Screening Linked to Increased Incidence of Many HPV-Related Cancers
For HPV-related cancers without standardized screening, incidence rates increased between 2001 and 2017.
PARP Inhibitor Maintenance Improves PFS in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer
Maintenance with a PARP inhibitor benefited all subsets of patients
Study Reports Improved Outcomes With Olaparib Maintenance in Ovarian Cancer
A team of investigators conducted a double-blind, placebo-controlled, phase 3 trial to assess outcomes following olaparib treatment in patients with BRCA 1/2-mutated, relapsed ovarian cancer.
Most Patients With Breast, Ovarian Cancer Do Not Undergo Genetic Testing
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Oral Contraceptives Protect Against Ovarian, Endometrial Cancer
Increased risk for breast cancer observed, which was seen for up to two years after discontinuation of oral contraceptives.
Is There a Survival Benefit for Patients with Advanced Ovarian Clear Cell Carcinoma Who Complete More Than 6 Cycles of Postoperative Chemotherapy?
[Cancer Management and Research] Retrospective review sought to determine how residual tumor diameter and number of cycles of adjuvant chemotherapy after surgery influenced prognosis for patients with OCCC.
Ovarian Cancer Treatment Regimens
Access a detailed treatment regimen chart for ovarian cancer, with a focus on primary chemotherapy/primary adjuvant therapy with IV and IP options.
Use of Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Has Doubled
Use of neoadjuvant chemotherapy for patients with stage IIIC and IV epithelial ovarian cancer has increased from 2004 to 2016.
Hyperthermic Intraperitoneal Chemotherapy May Improve Outcomes in Epithelial Ovarian Cancer
Hyperthermic intraperitoneal chemotherapy added to cytoreductive surgery improved outcomes compared with surgery alone in a cohort study.
- Loading...
Loading...
Next post in Ovarian Cancer
Loading... 
Loading...